Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: A study in China

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1591-1592

  Berry, Catherine ^a   Yates, Tom A ^b   Seddon, James A ^a,c   Phillips, Patrick P J ^b   Du Cros, Philipp ^a  

^a MÉDECINS SANS FRONTIÈRES   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANEMIA; CHINA; CLINICAL EFFECTIVENESS; CYTOPENIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LETTER; NEUROPATHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; MULTIDRUG RESISTANT TUBERCULOSIS; TREATMENT OUTCOME;

ANTITUBERCULAR AGENTS; CHINA; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; HUMANS; LINEZOLID; OXAZOLIDINONES; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84969900570     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01646-2015     Document Type: Letter

References (11)

1. Brigden G, Nyang'wa B-T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ 2014; 92: 68-74.
2. Tang S, Yao L, Hao X, et al. Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: A study in China. Eur Respir J 2015; 45: 161-170.
3. World Health Organization. WHO Model List of Essential Medicines. 2015. www.who.int/medicines/publications/essentialmedicines/en/Date last updated: August, 2015. Date last accessed: October, 2015.
4. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. 2014. http://apps.who.int/iris/bitstream/10665/130918/1/9789241548809-eng.pdf?ua=1&ua=1Date last accessed: October 2, 2015.
5. Winters N, Butler-Laporte G, Menzies D. Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. Eur Respir J 2015; 46: 1461-1470.
6. Caminero JA, Scardigli A. Classification of antituberculosis drugs: A new proposal based on the most recent evidence. Eur Respir J 2015; 46: 887-893.
7. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340.
8. Zhang X, Falagas ME, Vardakas KZ, et al. Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis. J Thorac Dis 2015; 7: 603-615.
9. Tang S, Yao L, Hao X, et al. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis 2015; 60: 1361-1367.
10. Marx FM, Dunbar R, Enarson DA, et al. The temporal dynamics of relapse and reinfection tuberculosis after successful treatment: A retrospective cohort study. Clin Infect Dis 2014; 58: 1676-1683.
11. Lee M, Song T, Kim Y, et al. Linezolid for XDR-TB: final study outcomes. N Engl J Med 2015; 373: 290-291.